Home Cart Sign in  
Chemical Structure| 1637739-82-2 Chemical Structure| 1637739-82-2

Structure of BQU57
CAS No.: 1637739-82-2

Chemical Structure| 1637739-82-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BQU57 shows selective inhibition for Ral relative to Ras or Rho and inhibit xenograft tumor growth similar to depletion of Ral by siRNA.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BQU57

CAS No. :1637739-82-2
Formula : C16H13F3N4O
M.W : 334.30
SMILES Code : N#CC(C1C2=CC=C(C(F)(F)F)C=C2)=C(N)OC3=C1C(C)=NN3C
MDL No. :MFCD28902198
InChI Key :IJCMHHSFXFMZAI-UHFFFAOYSA-N
Pubchem ID :77845606

Safety of BQU57

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of BQU57

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MDA-MB-468 50 μM 72 h BQU57 significantly decreased MDA-MB-468 cell viability. PMC8196523
MVT1 50 μM 72 h BQU57 significantly decreased MVT1 cell viability. PMC8196523
H2122, H358, H460, and Calu6 human lung cancer cells 10 μM 3 h Evaluate the effect of compounds on anchorage-independent growth, RBC8 and BQU57 inhibited soft agar colony formation in Ral-dependent cell lines H2122 and H358 PMC4351747
Wild-type and caveolin−/− mouse embryonic fibroblasts (MEFs) 15 μM 1 h Evaluate the effect of compounds on cell spreading, RBC6, RBC8, and RBC10 inhibited cell spreading only in WT MEFs PMC4351747
J82 human bladder cancer cells 50 μM 1 h Evaluate the effect of compounds on RalA activity, RBC6, RBC8, and RBC10 reduced the activation of RalA PMC4351747
MDA-MB-231 50 μM 72 h BQU57 significantly decreased TNBC cell line viability and sensitized cells to paclitaxel in vitro. PMC8196523

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice H2122 human lung cancer xenograft model Intraperitoneal injection 10/20/50 mg/kg Once daily (except weekends) for 21 days Evaluate the effect of Ral inhibitors on xenograft tumor growth, RBC8 and BQU57 significantly inhibited tumor growth PMC4351747
NSG mice MDA-MB-231 orthotopic mammary tumor model Intraperitoneal injection 50 mg/kg 3 times weekly until early removal criteria were met BQU57 significantly inhibited MDA-MB-231 orthotopic mammary tumor growth and spontaneous lung metastasis. PMC8196523

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.99mL

0.60mL

0.30mL

14.96mL

2.99mL

1.50mL

29.91mL

5.98mL

2.99mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories